See What HealthDay Can Do For You
Contact Us

Study Highlights Readmit Factors Post Atrial Flutter Ablation

Readmission rate found to be 18.19 percent

heart illustration

THURSDAY, Aug. 17, 2017 (HealthDay News) -- Recognition of factors associated with early readmission for patients after atrial flutter (AFL) ablation is necessary for reducing costs and improving quality of life, according to a study published online Aug. 11 in the Journal of Cardiovascular Electrophysiology.

Byomesh Tripathi, M.D., from Mount Sinai St Luke's-Roosevelt Hospital in New York City, and colleagues examined factors associated with early readmissions following AFL ablation. The National Readmission Database 2013 to 2014 was used to derive the study cohort.

The researchers found that the readmission rate was 18.19 percent among 5,552 patients (1,010 patients with 1,396 readmissions). Heart failure, atrial fibrillation, atrial flutter, respiratory complications, infections, bleeding, and stroke/transient ischemic attack were common etiologies for readmission (12.23, 11.13, 8.93, 9.42, 7.4, 7.39, and 1.89 percent, respectively). Preexisting heart failure, chronic pulmonary disease, anemia, malignancy, weekend admission (versus weekday admission), and length of stay of at least five days were significant multivariate predictors of 90-day readmission (hazard ratios, 1.30, 1.37, 1.23, 1.87, 1.23, and 1.39, respectively). Half of the readmissions occurred within 30 days of discharge.

"Identifying high-risk patients, careful discharge planning, and close follow-up post-discharge can potentially reduce readmission rates in AFL ablation patients," the authors write.

Abstract
Full Text (subscription or payment may be required)

Physician's Briefing

HealthDay

HealthDay is the world’s largest syndicator of health news and content, and providers of custom health/medical content.

Consumer Health News

A health news feed, reviewing the latest and most topical health stories.

Professional News

A news feed for Health Care Professionals (HCPs), reviewing latest medical research and approvals.